Discussion
CINV, vomiting
REGRESSION, DELETION
This study used a prospective randomized controlled trial to observe the antiemetic effect of chemotherapy patients with different genetic polymorphisms, and most similar studies at home and abroad have chosen this research method. In this study, we explored the association between the TP rate of olanzapine or aprepitant triple antiemetic regimen to prevent multi-day cisplatin-induced CINV and 36 CINV-related gene polymorphisms. The results showed that multiple polymorphisms were associated with CINV. The results of univariate analysis showed that CINV was correlated with rs1062613 is located in the promoter region of the The results of univariate analysis in this study showed that the non-GG genotype of The − 100_-102AAG deletion (rs45460698) located in the promoter region is a common polymorphism in the 5-HT3B subunit. Tremblay et al. found that in all Caucasian patients who experienced CINV, the frequency of vomiting was significantly increased in patients with − 100_-120delAAG deletion [SNP rs7943062 is located at the mutation site in the 3’ non-coding region of the The non-synonymous SNP of A study by Yokoi et al. examined 156 Japanese patients receiving cisplatin chemotherapy. In multivariate logistic regression analysis, Our univariate analysis found that olanzapine-treated patients had a delayed TP rate associated with the This study found that the incidence of CINV in patients with TT genotype at This study has not found any correlation between the following genes and CINV: The results of this experiment can conclude that the gene polymorphisms of This study has some limitations. First, this study did not measure antiemetic drug concentrations in plasma or cerebrospinal fluid, and no pharmacokinetic information was available. Therefore, we were unable to elucidate the basis of SNP action and the mechanism of response to antiemetics Secondly, the sample size used to analyze gene polymorphisms and TP rates is relatively small, so clinical studies with larger sample sizes are needed to provide stronger evidence support in the future.